Advanced lipid testing
While standard lipid screening plays an important role in risk assessment, residual cardiovascular risk can still be significant despite management of traditional risk factors.1
Recent data suggests that even after statin therapy, residual risk still exists in many patients.2
Going beyond standard lipid panels to assess lipoprotein and apolipoprotein risk factors may provide deeper insights into the residual risk of your patients.
Patients who may benefit from advanced testing include those with:
- Established CVD
- Diabetes
- Hypertension
- Metabolic syndrome
- Elevated LDL-C >=190 mg/dL
- >=5% estimated ASCVD risk
- Other traditional risk factors, including
- Age (men >45 years; post-menopausal women)
- Family history of premature onset of CVD
- Unhealthy diet, excessive alcohol intake, smoking, and/or stress
- Obesity
- Low HDL-C
Do more to identify residual risk
Cardiovascular risk assessment has evolved beyond lipid values to include inflammation, lipoprotein subfractions, and apolipoproteins. With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events.
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.
References
- Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997;95(1):69-75.
- National Cholesterol Education Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
Questions?
Your Quest account representative can provide additional information on our cardiovascular testing solutions.
Cardiovascular disease
Cardiovascular
-
Advanced lipid testing -
Identifying residual risk -
Inflammation testing -
Advanced inflammatory marker testing -
Metabolic testing -
Metabolic testing portfolio -
Cardiogenetic testing -
Heart failure -
Focus on earlier identification of heart failure risk -
Non-lipid markers for CVD -
Important genotyping -
CVD test descriptions -
4myheart® program -
Cardio IQ® report -
Early identification of CVD risk in women
Save time & fix billing issues
Avoid disruptions and reduce paperwork with electronic billing trailers.
Raise patient satisfaction and get the insights you need
Access better patient tools, view test offerings, improve your bottom line, and more.
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
-
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.